MedTrace Logo

Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke

NCT02433509 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-08-06

No results posted yet for this study

Summary

The objective of the study is to determine the safely of Human Umbilical Cord Blood mononuclear cells by Intravenous injection in acute ischemic stroke patients.

Conditions

  • Acute Ischemic Stroke

Interventions

OTHER

hUCB

1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used. 2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion .

Sponsors & Collaborators

  • Buddhist Tzu Chi General Hospital

    collaborator OTHER

  • StemCyte Taiwan Co., Ltd.

    collaborator INDUSTRY

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Shinn-Zong Lin, M.D.;PhD. · Buddhist Tzu Chi General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2023-06-14
Completion
2023-06-14

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433509 on ClinicalTrials.gov